NCT00994123View on ClinicalTrials.gov

A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

162

Participants

Timeline

Start Date

February 28, 2010

Primary Completion Date

November 30, 2014

Study Completion Date

June 30, 2015

Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
DRUG

MM-121

MM-121 (SAR256212) = intravenous solution

DRUG

Erlotinib

erlotinib = daily oral tablet

Trial Locations (38)

100

Taipei

10065

New York

14263

Buffalo

15232

Pittsburgh

29010

Málaga

29425

Charleston

30322

Atlanta

33305

Guishan

33612

Tampa

35294

Birmingham

37232

Nashville

40705

Taichung

45267

Cincinnati

47905

Lafayette

60488

Frankfurt

63110

St Louis

68167

Heidelberg

69126

Heidelberg

70146

Tainan City

75390

Dallas

80045

Aurora

85715

Tucson

89081

Ulm

92354

Loma Linda

94115

San Francisco

95817

Sacramento

97239

Portland

99437

Bad Berka

02114

Boston

Unknown

Edmonton

Montreal

Lungenklinik

Madrid

Taichung

M5G2M9

Toronto

135-710

Seoul

120-752

Seoul

08035

Barcelona

Sponsors
All Listed Sponsors
lead

Merrimack Pharmaceuticals

INDUSTRY

NCT00994123 - A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter